Perceptive Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Perceptive Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-51,200	Closed	-$60K	–	181
2016 Q1	$60K	Sell	51,200 -800,000	-94%	-$1.24M	0.01%	162
2015 Q4	$2.08M	Hold	851,200	–	–	0.15%	72
2015 Q3	$2.55M	Hold	851,200	–	–	0.2%	73
2015 Q2	$3.52M	Sell	851,200 -348,800	-29%	-$1.39M	0.21%	79
2015 Q1	$5.2M	Buy	+1,200,000	New	+$4.33M	0.4%	49
2014 Q3	–	Sell	-1,500,000	Closed	-$3.79M	–	127
2014 Q2	$3.79M	Buy	+1,500,000	New	+$3.2M	0.37%	49

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCM

Tanaka Capital Management New York $59.9M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Perceptive Advisors's CPRX Position: Q2 2016 in Review

Perceptive Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2016, closing a stake of 51,200 shares — an estimated $60K sold.

Perceptive Advisors first reported a position in CPRX in Q2 2014 and held it in 6 quarters. The position peaked at $5.2M in Q1 2015. 62 funds tracked by Wall St. Rank hold CPRX as of Q2 2016.

Perceptive Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2016 after selling out during the quarter.
Perceptive Advisors sold 51,200 Catalyst Pharmaceutical shares in Q2 2016, an estimated $60K.
Perceptive Advisors first reported a position in Catalyst Pharmaceutical in Q2 2014 and held it in 6 quarters.
Perceptive Advisors's Catalyst Pharmaceutical position peaked at $5.2M in Q1 2015.
62 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2016.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.